Astellas Pharma (OTCMKTS:ALPMY) Issues Quarterly Earnings Results

Astellas Pharma (OTCMKTS:ALPMY) posted its quarterly earnings data on Wednesday. The company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.41 by ($0.06), Zacks reports. Astellas Pharma had a return on equity of 25.79% and a net margin of 16.01%.

Astellas Pharma Trading Down 0.1%

Shares of OTCMKTS ALPMY traded down $0.01 during midday trading on Wednesday, reaching $16.11. 72,842 shares of the stock were exchanged, compared to its average volume of 148,332. The business has a 50-day simple moving average of $15.03 and a two-hundred day simple moving average of $14.73. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.20 and a quick ratio of 0.93. The company has a market capitalization of $29.15 billion, a price-to-earnings ratio of 12.26 and a beta of 0.06. Astellas Pharma has a 12 month low of $10.64 and a 12 month high of $17.35.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Astellas Pharma presently has a consensus rating of “Moderate Buy”.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its research and commercial activities focus on areas including oncology, urology, immunology, neuroscience, ophthalmology and rare diseases. The company serves patients and healthcare providers in Japan, North America, Europe and other international markets.

Astellas’ portfolio includes medicines such as Xtandi (enzalutamide) for certain prostate cancers, Xospata (gilteritinib) for acute myeloid leukemia, Prograf (tacrolimus) for transplant-related immunosuppression, and Myrbetri (mirabegron) for overactive bladder.